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HER4/ErbB4 is a ubiquitously expressed member of
the EGF/ErbB family of receptor tyrosine kinases that
is essential for normal development of the heart, ner-
vous system, and mammary gland. We report here
crystal structures of the ErbB4 kinase domain in
active and lapatinib-inhibited forms. Active ErbB4
kinase adopts an asymmetric dimer conformation
essentially identical to that observed to be important
for activation of the EGF receptor/ErbB1 kinase. Mu-
tagenesis studies of intact ErbB4 in Ba/F3 cells con-
firm the importance of this asymmetric dimer for ac-
tivation of intact ErbB4. Lapatinib binds to an inactive
form of the ErbB4 kinase in a mode equivalent to its
interaction with the EGF receptor. All ErbB4 residues
contacted by lapatinib are conserved in the EGF
receptor and HER2/ErbB2, which lapatinib also tar-
gets. These results demonstrate that key elements
of kinase activation and inhibition are conserved
among ErbB family members.INTRODUCTION
HER4/ErbB4 is a member of the epidermal growth factor (EGF)/
ErbB family of receptor tyrosine kinases (Carpenter, 2003; Plow-
man et al., 1993), which in humans, also includes the epidermal
growth factor (EGF) receptor (EGFR/ErbB1/HER1), ErbB2
(HER2/Neu), and ErbB3 (HER3) (Holbro and Hynes, 2004;
Yarden and Sliwkowski, 2001). Each ErbB receptor is essential
for normal animal development (Olayioye et al., 2000), and ab-
normal expression and activation of ErbBs are associated with
many human cancers (Hynes and Lane, 2005). Loss of ErbB4
function in particular results in defects in the heart, nervous
system, and mammary gland in mice (Gassmann et al., 1995;
Tidcombe et al., 2003).
ErbBs mediate their biological effects through ligand-depen-
dent elevation of their tyrosine kinase activities. ErbBs consist
of an extracellular ligand-binding region, a single membrane-
spanning region, a cytoplasmic kinase domain, and a 220–350460 Structure 16, 460–467, March 2008 ª2008 Elsevier Ltd All rightsamino acid C-terminal ‘‘tail’’ that becomes tyrosine phosphory-
lated following activation and mediates interactions between
ErbBs and downstream effectors (Burgess et al., 2003). Ligand
binding to the extracellular region results in formation of specific
ErbB homo- and heterodimers, activation of the cytoplasmic ki-
nase, and initiation of intracellular signaling cascades (Yarden
and Sliwkowski, 2001). Despite 60%–75% sequence identity,
mechanistic differences beyond ligand and effector specificity
have emerged among ErbB receptors. Both ErbB1 and ErbB4
behave in an archetypal manner and homodimerize and signal
in response to ligand binding (Ferguson et al., 2000; Carpenter,
2003). ErbB2, however, lacks a known ligand and fails to homo-
dimerize in normal circumstances. ErbB2 acts instead as a uni-
versal heterodimerization partner for each of the other ErbBs
regardless of the stimulating ligand (Karunagaran et al., 1996;
Klapper et al., 1999). An additional combination of properties
is observed for ErbB3, which binds and responds to ligands
but fails to homodimerize (Ferguson et al., 2000; Berger et al.,
2004). The ErbB3 kinase domain appears to be inactive (Sierke
et al., 1997), and ErbB3 must heterodimerize, most notably
with ErbB2, to signal.
Structural studies of ErbBs have established a molecular con-
text for understanding many features of ErbB signaling. Crystal-
lographic studies of the extracellular regions of ErbB1, ErbB3,
and ErbB4 show them to be made up of four discrete subdo-
mains that adopt an autoinhibited conformation in the absence
of ligand (Bouyain et al., 2005; Burgess et al., 2003; Cho and
Leahy, 2002; Ferguson et al., 2003). Ligand binding promotes
a domain rearrangement that exposes previously obscured sur-
faces and allows them to mediate dimerization (Burgess et al.,
2003; Garrett et al., 2002; Ogiso et al., 2002). In contrast, crystal
structures of the ErbB2 extracellular region show it to adopt
a fixed, active-like structure in which the canonical ligand-bind-
ing surfaces are involved in an interdomain interaction (Cho et al.,
2003; Garrett et al., 2003). These unique interactions rationalize
the absence of an ErbB2 ligand and the role of ErbB2 as a univer-
sal ErbB heterodimerization partner.
Active kinases are characterized by several conformational
features including the relative orientation of N- and C-terminal
lobes, the disposition of the ‘‘activation’’ loop, the orientation
of the aC helix, and formation of a salt bridge involving a gluta-
mate on the aC helix (Huse and Kuriyan, 2002). Recently,reserved
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HER4/ErbB4 Kinase Activation and Inhibitionformation of a crystallographically observed asymmetric dimer
between EGFR kinase domains was shown to correlate with
the presence of an activated kinase conformation and to be re-
quired for EGFR activation (Zhang et al., 2006). In this asymmetric
kinase domain dimer, the C lobe of a ‘‘donor’’ contacts the N lobe
of an adjacent ‘‘acceptor’’ and promotes conformational
changes that activate the acceptor kinase. This type of activating
interaction is reminiscent of the activating interaction between
cyclins and the N lobes of cyclin-dependent kinases and was
suggested to be conserved in other ErbBs based on amino acid
sequence conservation (Jeffrey et al., 1995; Zhang et al., 2006).
Understanding the molecular details of ErbB activation has
direct clinical relevance. ErbB activation is associated with several
human cancers, and drugs targeting ErbB1 and/or ErbB2 have
been approved for treatment of breast, lung, and colon cancers
(Johnston etal., 2006). These drugs include several small molecule
kinase inhibitors, such as the 4-aniloquinazolines erlotinib (Tar-
ceva), gefitinib (Iressa), and lapatinib (Tykerb), which all bind com-
petitivelyat the ATP-binding siteof the kinase (Denny, 2001; Petrov
et al., 2006). Whereas erlotinib and gefitinib are relatively specific
for ErbB1, lapatinib inhibits all active ErbB kinases (Wood et al.,
2004). Activation of ErbB1 and ErbB2 clearly contributes to
adverse tumor characteristics, but the converse may be true for
ErbB4. Several observations suggest thatErbB4 activation inhibitsStructure 1cell proliferation and promotes apoptosis (Karamouzis et al.,
2007). For this reason, development of ErbB inhibitors that specif-
ically target ErbB1 and ErbB2 but not ErbB4 may prove beneficial.
To investigate the molecular details of activation and inhibition
of the ErbB4 kinase, we have determined crystal structures of the
ErbB4 kinase in the presence and absence of lapatinib. Without
lapatinib, the ErbB4 kinase adopts an active conformation and
forms an asymmetric dimer virtually identical to the activating di-
mer observed for EGFR. A low-resolution structure of an inactive
form of the ErbB4 kinase was also obtained in the absence of
lapatinib. Mutagenesis studies confirm the importance of this
dimerization mode for ErbB4 activation. With bound lapatinib,
the ErbB4 kinase adopts a conformation characteristic of inac-
tive kinases and does not make the EGFR-like asymmetric di-
mer. Lapatinib binds to ErbB4 in a mode similar to its interaction
with the EGFR kinase. All residues contacting lapatinib are con-
served in both EGFR and ErbB4, which implicates kinase ele-
ments not directly involved in inhibitor contact in defining the
different inhibitory parameters of lapatinib for EGFR and ErbB4.
RESULTS
The HER4/ErbB4 kinase was expressed by using a baculovirus
expression system, purified, and crystallized in three differentTable 1. Crystallization, Data Collection, and Refinement Statistics
Crystal
ErbB4 Kinase Complexed
with Lapatinib (Type I)
ErbB4 Kinase
Domain (Type II)
ErbB4 Kinase
Domain (Type III)
Crystallization conditions 4.3 M NaCl, 0.1 M HEPES
(pH 7.0), 2% trifluoroethanol
15% PEG3350, 0.1 M Tris
(pH 8.5)
2.2 M NaCl, 0.2 M MgCl2, 0.1
M HEPES (pH 7.0), 2%
hexafluoroisopropanol
Spacegroup P61 P32 P61
Unit cell (A˚) a = b = 102.6, c = 185.1 a = b = 86.7, c = 120.0 a = b = 102.7, c = 181.3
Resolution range (A˚) 30.0–2.80 (3.00–2.80) 30.0–2.50 (2.59–2.50) 30.0–4.0 (4.14–4.00)
Molecules per ASU 2 3 2
Solvent content 68% 47.5% 68%
Data completeness (%) 99.9 (99.6) 100 (100) 98.6 (93.3)
Redundancy 4.8 2.6 7.5
Rsym (%) 6.2 (51.4) 10.7 (45.7) 25.3 (66.7)
I/sI 24.5 (2.8) 8.8 (1.9) 7.6 (2.9)
Refinement
Phaser Search model 1XKK 1M14 3BBT without lapatinib
R/Rfree (%) 25.0/28.9 20.2/25.5 30.2/35.4
Number of protein atoms 4357 6846 4354
Number of nonprotein/
solvent atoms
71 1 0
Number of solvent atoms 84 173 0
Ramachandran Plot
Most favored (%) 89.2 89.6 84.8
Additional allowed (%) 9.7 9.9 13.9
Generously allowed (%) 1.1 0.5 1.3
Rmsd bond length (A˚) 0.01 0.01 0.01
Rmsd bond angle () 1.3 1.3 1.6
Mean B value 26.2 19.2 63.7
PDB code 3BBT 3BCE 3BBW6, 460–467, March 2008 ª2008 Elsevier Ltd All rights reserved 461
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HER4/ErbB4 Kinase Activation and Inhibitioncrystal forms (Table 1). The ErbB4 kinase structure in each crys-
tal form was determined by molecular replacement with EGFR
kinase structures as search models (Stamos et al., 2002; Wood
et al., 2004; Zhang et al., 2006). Type I crystals were grown in
the presence of the pan-ErbB inhibitor lapatinib and diffracted
to 2.8 A˚ Bragg spacings. The ErbB4 kinase in these crystals
adopts an inactive-like conformation (Figure 1B) (Huse and Kur-
iyan, 2002). Type II and type III crystals were grown in the pres-
ence of AMP-PNP and diffracted to 2.5 and 4.0 A˚ Bragg spac-
ings, respectively. In type II crystals, the ErbB4 kinase adopts
an active-like conformation and forms the same asymmetric di-
mer interaction shown to be important for activation of the EGFR
kinase (Zhang et al., 2006; Figures 1A and 2). The ErbB4 kinase is
a monomer in solution at 15 mM as judged by both analytical ul-
tracentrifugation and size-exclusion chromatography, indicating
that, similar to the EGFR kinase, the kinase dimer interaction is
relatively weak. A ‘‘symmetric dimer’’ equivalent to that observed
for the EGFR kinase domain was not observed (Stamos et al.,
2002). Type III crystals grew in the same space group with similar
cell constants as type I crystals, and the ErbB4 kinase domain in
these crystals also adopts an inactive-like conformation. Theseare the first crystals of an ErbB kinase domain in an inactive
conformation not grown in the presence of either an inhibitor or
a dimer-targeting mutation (Zhang et al., 2006). The existence
of this crystal form suggests that high salt conditions may influ-
ence the conformational equilibria of this kinase.
The kcat, Km
app for ATP, Km
app for a peptide substrate (GGME-
DIYFEFMGGKKK), and IC50 and Ki
app for lapatinib were also
measured for the ErbB4 kinase and compared with values deter-
mined for the ErbB2 kinase domain of kcat, Km
app ATP, and Km
app
for the same peptide substrate (Table 2). These results are gen-
erally comparable to published values with the exception that the
kcat for ErbB4 is 10-fold greater than previously measured
(Brignola et al., 2002).
All 17 C-lobe residues involved in the asymmetric dimer con-
tact are conserved between ErbB4 and EGFR; 14/18 ErbB4
N-lobe residues involved in this contact are also conserved in
EGFR. The ErbB4 asymmetric dimer buries 2252 A˚2 with a shape
complementarity value of 0.657 (Lawrence and Colman, 1993).
Comparable values for the EGFR asymmetric dimer are 2077
A˚2 and 0.614. As observed for the EGFR asymmetric kinase
dimer, the subunits of the asymmetric ErbB4 kinase dimer areFigure 1. Ribbon Diagrams of ErbB4 Kinase
Structures
(A) The active conformation of the ErbB4 kinase.
The activation loop is colored red.
(B) An inactive conformation of the ErbB4 kinase in
complex with lapatinib, which is shown as a red
stick model. The activation loop is disordered,
but the loop termini are colored red.
(C) Superposition of the active and inactive confor-
mations of the ErbB4 kinase.Figure 2. Superposition of the Asymmetric
Dimers of EGFR and ErbB4 Kinase
The ErbB4 kinase subunits are colored blue and
cyan. An EGFR dimer is colored light yellow.
Only the single blue colored ErbB4 kinase subunit
and corresponding EGFR subunit were included in
the superposition.
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HER4/ErbB4 Kinase Activation and Inhibitionrelated by a crystallographic 3-fold screw axis (Zhang et al.,
2006). If single subunits of the EGFR and ErbB4 kinase asymmet-
ric dimer are superimposed, the positions of the other dimer sub-
units are related by a 7 rotation such that structural elements
distant from the dimer interface superimpose progressively less
well (Figure 2). This slight difference seems unlikely to have any
functional consequences. To validate the importance of the
asymmetric dimer for ErbB4 function, selected substitutions of
both N- and C-lobe interface residues were introduced into
full-length ErbB4. In each case, these substitutions diminish
ligand-dependent autophosphorylation (Figure 3), similar to the
effect of equivalent mutations in EGFR (Zhang et al., 2006).
Curiously, no electron density for a bound nucleotide is observed
in type II crystals despite the active kinase conformation and the
presence of 1 mM AMP-PNP in the crystallization buffer. No
electron density consistent with tyrosine phosphorylation is
observed.
Figure 3. Receptor Activation Assay
(A) Western blot analysis of the indicated ErbB4 variants immunoprecipitated
from cell lysates following treatment with or without Neuregulin-2b (NRG-2b).
Blots were probed with an anti-phosphotyrosine antibody (top) or anti-ErbB4
antibody (bottom).
(B) Quantitation of western blot band intensities. The results are the mean and
standard deviation from three independent experiments.Structure 1Electron density for lapatinib is present in type I crystals (Fig-
ure 4). The moderate resolution of type I crystals (2.8 A˚) and
the weak electron density for lapatinib limit clear interpretation
of specific lapatinib conformations, but the lapatinib binding
mode appears similar to its binding to the EGFR kinase (Figure 4)
(Wood et al., 2004). No electron density is observed for the sul-
fone-furanyl moiety, and it was not included in the atomic model.
Satisfactory density exists for the fluorophenyl and quinazolin-
amine moieties and inspection of difference electron density
maps strongly suggests that the phenyl group on the fluoro-
phenyl is flipped 180 relative to its orientation in the lapatinib-
EGFR complex, altering the relative position of the fluoro group
(Figure 4). In addition, a slight movement of the aC helix, which
contacts the fluoro group, is observed in ErbB4 complex relative
to EGFR complex. Incomplete density exists for the internal
chlorophenyl ring, with one carbon extending outside of clear
density despite extensive modeling of different possible confor-
mations (Figure 4A).
We have characterized the lapatinib-bound ErbB4 kinase con-
formation as inactive based on the location and orientation of the
N and C lobes, the disposition of the aC helix, and the absence of
a key salt bridge involving a glutamate on helix aC. Most of the
activation loop in lapatinib-bound ErbB4 was disordered and
not modeled (residues 844 to 857). It is therefore not clear
whether there are direct inhibitory interactions between the acti-
vation loop and the aC helix in unactivated ErbB4. In EGFR, ali-
phatic side chains from a short helix in the activation loop interact
directly with, and appear to buttress, a displaced helix aC (Zhang
et al., 2006; Wood et al., 2004). Replacing these side-chains with
polar groups disrupts the activation loop/helix aC interaction and
elevates the basal activity of the kinase. We are not able to deter-
mine whether similar autoinhibitory interactions occur in the
inactive ErbB4 kinase structure. The relevant amino acids in
the activation loop are conserved, however, and the L839R mu-
tation enhances basal activity of ErbB4 just as the analogous
L834R mutation does in EGFR (Figure 3).DISCUSSION
Discovery of the importance of an asymmetric EGFR kinase
dimer for regulation of kinase activity provided a satisfying link
between ligand-induced receptor dimerization and kinase acti-
vation (Burgess et al., 2003; Jeffrey et al., 1995; Zhang et al.,
2006). Our observation of an essentially identical asymmetric di-
mer of the ErbB4 kinase and its importance for ErbB4 signaling
provides strong support for its generality among ErbB family
members. The asymmetric dimer mechanism introduces a new
point of regulation of ErbBs that may be exploited by cellularTable 2. Enzymatic Parameters
Km
app ATP (mM) Km
app Peptide (mM) kcat (min
1) [Mn2+] (mM) IC50 Lapatinib (mM) Ki
app Lapatinib (nM)
ErbB4 KD 10 ± 2 169 ± 35 52 ± 10 2 1.4 ± 0.1 700
ErbB2 KD 24 ± 3 57 ± 5 6.1 ± 0.2 10 — —
EGFR ICDa 5 899 ± 200 1.32 0.62 — 3 ± 0.2
ErbB2 ICDa 13 157 ± 40 3.60 1.60 — 13 ± 1
ErbB4 ICDa 21 144 ± 22 5.58 0.20 >1 347 ± 16
a Previously reported values (Brignola et al., 2002; Wood et al., 2004).6, 460–467, March 2008 ª2008 Elsevier Ltd All rights reserved 463
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HER4/ErbB4 Kinase Activation and Inhibitionfactors or targeted therapies and is consistent with earlier obser-
vations of trans-phosphorylation among receptor tyrosine ki-
nases (Ballotti et al., 1989; Lammers et al., 1990; Zhang et al.,
2007). In the asymmetric dimer, one kinase is the ‘‘donor’’, and
the other is the ‘‘acceptor’’. The C-terminal tail of the donor is ad-
jacent to the acceptor active site and readily phosphorylated, but
the C-terminal tail of the acceptor is on the opposite side of the
dimer >75 A˚ away from the donor active site, which is unable to
phosphorylate the acceptor tail.
Lapatinib inhibits ErbB4 kinase activity but less well than it in-
hibits EGFR and ErbB2 (Table 2) (Brignola et al., 2002), but
a comparison of the EGFR-lapatinib and ErbB4-lapatinib com-
plex structures reveals no obvious explanation for this differ-
ence. Although the resolution of the the ErbB4-lapatinib struc-
ture is moderate, 2.8 A˚, it is clear that lapatinib binds EGFR464 Structure 16, 460–467, March 2008 ª2008 Elsevier Ltd All rightsand ErbB4 in the same binding site, and all residues that come
into van der Waals contact with lapatinib (atoms <4 A˚ apart)
are conserved between EGFR and ErbB4 (and ErbB2) (Table
S1, see the Supplemental Data available with this article online).
The only notable difference between the binding mode of lapati-
nib to EGFR and ErbB4 is a flip of the fluorophenyl ring, which
alters the position of the fluorine but does not introduce or break
contacts with residues not found in both EGFR and ErbB4 (Fig-
ure 4). This observation suggests that ErbB kinase elements
not directly contacting lapatinib must contribute to the distinctive
effects of lapatinib on EGFR and ErbB4 activity. Since lapatinib
appears to bind preferentially to an inactive kinase conformation,
one possibility is that ErbB elements that influence the intercon-
version between active and inactive states of the kinase, either
by influencing the nature of intermediate states or the rates ofFigure 4. Bound Lapatinib
(A) The 2Fo-Fc simulated annealing omit map for lapatinib contoured at 1s. The structure of ErbB4 kinase is colored yellow, and lapatinib is shown as a red stick
model. The structure of the EGFR kinase-lapatinib complex is superimposed with the EGFR kinase colored pale cyan and lapatinib green.
(B) Chemical structure of lapatinib.reserved
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HER4/ErbB4 Kinase Activation and Inhibitiontheir interconversion, are important components of inhibitor
effectiveness (Levinson et al., 2006).
The different kinetic parameters obtained for ErbB kinases
may reflect such differences in the balancing of factors that influ-
ence equilibria between active and inactive kinase conforma-
tions. As noted by Zhang et al. (2006), activity of the EGFR kinase
increases at either higher concentrations or when the L834R
substitution is introduced into the activation loop. These authors
note that these observations indicate some level of autoinhibition
in the isolated EGFR kinase, which may be overcome by either
increases in concentration or mutation. The kcat we measure
for ErbB4 with a specific peptide substrate is 10-fold faster
than previously reported for other ErbBs including ErbB4, sug-
gesting our ErbB4 kinase may be intrinsically more active than
other ErbBs. For comparison, the kcat we measure for ErbB2,
which is 10-fold less than measured for ErbB4 (Table 2), is in
line with previously reported values (Table 2; Brignola et al.,
2002). A possible explanation for this difference is that earlier au-
thors worked with a larger fragment of the ErbB4 intracellular do-
main compared to our fragment, and the additional ErbB4 resi-
dues may have an autoinhibitory effect. A similar effect is not
observed for longer versions of ErbB2, however, possibly indi-
cating a different distribution of kinase control mechanisms (Ta-
ble 2; Brignola et al., 2002). The reduced sensitivity to lapatinib
and the increased kcat for the ErbB4 kinase domain suggests
that its equilibrium state may be biased toward the active form
relative to EGFR. It is clear that even in the presence of shared
regulatory mechanisms, fine tuning the details of ErbB kinase ac-
tivity can have important effects on the response of ErbB recep-
tors to various natural and artificial stimuli.
EXPERIMENTAL PROCEDURES
Expression and Purification of the ErbB4 Kinase Domain
A DNA fragment encoding residues 677–1004 of human ErbB4 was cloned into
a modified pFASTBac vector. Amino-acid numbering refers to the Jma isoform
and begins with the mature protein. This vector directs expression of the ErbB4
kinase region with an N-terminal strep II tag followed by a Tobacco Etch Virus
(TEV) protease recognition site. Recombinant bacmid (Bac-to-Bac expression
system, Invitrogen) was then transfected into Sf9 cells to produce recombinant
baculovirus. Sf9 cells were grown in suspension, infected by the virus, and har-
vested 3 days after infection. Cell pellets were lysed by sonication in 50 mM
Tris (pH 8.0), 150 mM NaCl, 10% glycerol, 1 mM DTT, and 1 mM PMSF. The
lysate was centrifuged at 30,000 3 g for 30 min. The supernatant was loaded
onto a 5 ml Strep-Tactin Superflow column (IBA). Attached proteins were
eluted by using the lysis buffer plus 2.5 mM desthiobiotin. ErbB4 kinase con-
taining fractions were treated with TEV protease overnight at 4C to remove
the N-terminal strep II tag, and the samples applied to a Ni-NTA column to re-
move the His-tagged TEV protease. The Ni-NTA column flow through was col-
lected and concentrated before loading onto a Superdex 75 size-exclusion
column (Amersham). Fractions containing the kinase were pooled and con-
centrated to 4 mg/ml in the column buffer (20 mM Tris [pH 8.0], 150 mM
NaCl, 1 mM DTT).
Kinase Assays
To determine ErbB kinetic parameters, radiometric kinase assays were carried
out in 50 mM HEPES (pH 7.5), 2 mM MnCl2, 37.5 mM NaCl, 1 mM DTT, 5%
Glycerol, and 125 mg/ml BSA with Biotin-GGMEDIYFEFMGGKKK as the pep-
tide substrate in a 25 ml reaction volume. The peptide substrate was prepared
by using standard Fmoc solid-phase peptide synthesis followed by coupling
biotin to the N terminus by using NHS-activated biotin (NovaBiochem) and pu-
rification by reverse phase HPLC. Reactions were initiated by the addition of
25–50 nM kinase, carried out for 3–6 min at 30C, and stopped by the additionStructure 1of 10 ml of 100 mM EDTA. To each sample, 10 ml of 10 mg/ml avidin was added,
and all samples were transferred to centrifugal filtration units with 30,000
NMWL membranes (Millipore) and washed three times with 100 ml wash solu-
tion (0.5 M Phosphate, 0.5 M NaCl [pH 8.5]). The Km
app for peptide substrate
was determined with varying peptide concentrations (870, 435, 218, 109,
54.4, 27.2, and 13.6 mM) and fixed ATP concentration (100 mM), and the Km
app
for ATP was determined by using varying ATP concentrations (120, 60, 30, 15,
7.5, 3.8, and 1.9 mM) and fixed peptide substrate concentration (435 mM). For
the IC50 determination, the lapatinib (160, 40, 10, 2.5, 0.625, 0.156, and 0.039
mM) was preincubated with the enzyme on ice for 30 min, and the reactions
were run with 10 mM ATP, 150 mM peptide, and 0.15% DMSO. Reactions for
the HER2 kinase domain were performed under the same conditions with
the exception that 10 mM MnCl2 and 320 nM kinase were used. Activities
proved to be linear with time and kinase concentration in the ranges used,
and the limiting substrate turnover was less than 10% for all rate measure-
ments. Duplicate measurements were generally within 20%. Apparent Km
and kcat values were obtained from nonlinear curve fits to the Michaelis-
Menten equation and the apparent Ki calculated assuming linear competitive
inhibition versus ATP. Lapatinib was synthesized following published methods
(Petrov et al., 2006).
Crystallization and Structure Determination
The ErbB4 kinase domain was incubated with either 0.2 mM lapatinib or 1 mM
AMP-PNP and 2 mM MgCl2 on ice for 1 hr before setting up crystallization
trials. All crystals were obtained by the hanging-drop method with a 1:1 mix-
ture of the stock protein solution and the crystallization buffer. Crystals of
the ErbB4 kinase complexed with lapatinib were grown in 4.3 M NaCl, 0.1 M
HEPES (pH 7.0), and 2% trifluoroethanol. Crystals were transferred to 2.7 M
sodium malonate (pH 7.0) as a cryoprotectant immediately prior to freezing
in liquid nitrogen. Crystals of the kinase with AMP-PNP were obtained in two
different conditions. Type I crystals were grown in 15% PEG3350, 0.1 M Tris
(pH 8.5), and cryoprotected by addition of 10% glycerol to the crystallization
solution immediately prior to freezing. Type III crystal were grown in 2.2 M
NaCl, 0.2 M MgCl2, 0.1 M HEPES (pH 7.0), 2% hexafluoroisopropanol, and
cryoprotected by addition of 15% glycerol to the crystallization solution imme-
diately prior to freezing. Diffraction data were collected at the Brookhaven
NSLS X4C beamline. The data were processed with HKL2000 (Otwinowski
and Minor, 1997). The structures were determined by molecular replacement
with the program PHASER (Storoni et al., 2004) and structures of the EGFR ki-
nase domain with lapatinib (1XKK) and apo-EGFR kinase (1M14) as the search
models, respectively. The program COOT (Emsley and Cowtan, 2004) was
used for model building, and CNS (Brunger et al., 1998) and REFMAC (Murshu-
dov et al., 1997) were used for refinement. TLS groups were generated by
TLSMD and used for refinement in REFMAC (Winn et al., 2001).
The ErbB4-lapatinib complex crystals belong to space group P61 and con-
tain two molecules in an asymmetric unit. Residues from 683–843 and 858–
973 are visible in the electron density and included in the model. The activation
loop (residues 844 to 857), 6 residues at the N terminus, and 31 residues at the
C terminus were not visible in the electron density map and not included in the
model. The ErbB4 kinase domain crystals grown in the presence of AMP-PNP
belong to space group P32, contain three molecules in an asymmetric unit, and
diffract to 2.5 A˚ Bragg spacings. Residues from 678 to 965 are visible in the
electron density and included in the model. Thirty-nine residues at the C ter-
minus are not visible and not included in the model. No electron density for
a bound nucleotide is observed or included in the model. Diffraction data
and refinement statistics are summarized in Table 1.
Receptor Activation Assays
Wild-type human ErbB4 JmbCyt2 isoform in pcDNA3.1(+) was kindly provided
by Graham F. Carpenter (Vanderbilt University), and a Neuregulin-2 expression
plasmid kindly provided by David Riese (Purdue). Point mutations were gener-
ated by site-directed mutagenesis by using the Quikchange method (Strata-
gene, La Jolla, CA). Ba/F3 cells were maintained in RPMI-1640 media supple-
mented with 10% fetal bovine serum (FBS), 10 mM HEPES, 2 mM sodium
pyruvate and IL-3 (1 ng/ml). Plasmids directing expression of wild-type or
mutated ErbB4 were electroporated into Ba/F3 cells by using an Electrocell
manipulator (ECM600, BTX Genetronics, San Diego, CA). Transfected cells
were selected in medium containing 1 mg/ml G418 for 2 weeks, and viable6, 460–467, March 2008 ª2008 Elsevier Ltd All rights reserved 465
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machine (BD Biosciences, San Jose, CA) for ErbB4 surface expression level
by using anti-ErbB4 antibody (Ab1) (Neomarkers, Fremont, CA) and R-phyco-
erythrin conjugated goat anti-mouse antibody (Invitrogen, Carlsbad, CA). Cells
were serum starved for 24 hr in supplemented RPMI-1640 media (described
above) lacking FBS. Starved cells were prechilled on ice and incubated for
10 min in ice-cold starvation medium containing 200 ng/ml NRG2b, produced
as described (Wilson et al., 2007). Cells were pelleted, washed extensively in
phosphate-buffered saline (PBS), lysed in RIPA buffer (1% Na deoxycholate,
1% NP-40, 0.1% SDS, 150 mM NaCl, 10 mM Na phosphate buffer [pH 7.2],
1 mM PMSF, 1 mg/ml leupeptin, 1 mg/ml aprotinin, 25 mM NaF, 5 mM
Na2MoO4, 0.2 mM Na3VO4). ErbB4 receptors were immunoprecipitated with
anti-ErbB4 (C18) (Santa Cruz Biotechnology, Santa Cruz, Ca) antibody and
subjected to western blot analysis with anti-ErbB4 antibody and phospho-
tyrosine antibody (PY20) (Zymed Laboratories, Inc., San Francisco, CA). Re-
ceptor activation in Figure 3 was normalized for receptor expression level by
dividing band intensities in the anti-phosphotyrosine western blots by the in-
tensities of the corresponding bands in anti-ErbB4 western blots. The ratio
of this value to the value obtained for wild-type ErbB4 with added NRG2b (ar-
bitrarily set to 1 in each experiment) was then calculated and is displayed in
Figure 3B. Intensities were quantified using Kodak Molecular Imaging software
(v. 4.0.3). Mean ± standard deviation for three independent experiments are
plotted.
ACCESSION NUMBERS
Atomic coordinates of type I, II, and III ErbB4 crystals have been entered into
the Protein Data Bank under the accession numbers 3BBT, 3BCE, and 3BBW,
respectively.
SUPPLEMENTAL DATA
Supplemental Data include a listing of ErbB4 residues with atoms within 4 A˚ of
lapatinib atoms along with EGFR and ErbB2 residues found at homologous
positions and can be found with this article online at http://www.structure.
org/cgi/content/full/16/3/460/DC1/.
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